Medicago overview. Update on plant-made VLPs. Influenza virus-like particle production in plants. Transient expression in N.
|
|
- Lucinda Jordan
- 7 years ago
- Views:
Transcription
1 Medicago overview Focus Vaccines & Proteinbased pharmaceuticals Update on plantmade VLPs Manufacturing technology Transient expression in tobacco Vaccine technology Viruslike particles Employees 240 Headquarters, laboratories & cgmp facilities Quebec City, CANADA Research Triangle Park, NC, USA Genopole d Evry, FRANCE Nathalie Landry Vice President Product Development landryn@medicago.com Corporate structure Public company from 2006 Sept 2013 Private company since Sept 2013 Mitsubishi Tanabe Pharma Corporation (majority shareholder) WHO meeting May 6 th Transient expression in N. benthamiana Influenza viruslike particle production in plants Influenza hemagglutinins accumulate at the plasma membrane forcing curvature of the membrane and budding of viruslike particles DNA sequence plants Infiltration Incubation No need for NA: No sialic acid in plants Extraction Purification VLP Flu virus From D Aoust et al., Plant Biotechnology Journal, Volume 8: (2010) 3 4 1
2 Rotaviruslike particle production in plants Rotavirus particle assembly Multistep process initiated in the cytosol and completed in the ER Requires 4 structural antigens: VP2, VP6, VP7, VP4 Plantproduced rotaviruslike particles Clinical development overview and status update Clinical trials Pandemic vaccine Phase I H5 VLP Alhydrogel completed in healthy adults (1860 years of age) Phase II H5 VLP Alhydrogel completed in healthy adults (1860 years of age) Phase I H5 VLP GLA completed in 2013 (IDRI s trial) 100 healthy adults (1849 years of age) First trial evaluating an adjuvant with intradermal administration H5 VLP Alhydrogel compared well with all other formulations GLAAF increased crossreactivity of antibodies Phase II H5 VLP GLA or Alhydrogel initiated in healthy adults (1860 years of age) All subjects received 2 doses, no SAEs Analysis of immune response ongoing All rights reserv From ed Trask et al., Nature Reviews Microbiology, Volume 10: (2012) 5 Phase I H7 VLP Alhydrogel initiated at beginning of healthy adults (1860 years of age) Completed Ongoing 6 Clinical development overview and status update Clinical trials Seasonal vaccine Phase I H1 VLP completed in 2011 (nonadjuvanted) 100 healthy adults (1849 years of age) The 5 microgram dose met the CHMP criteria Good antibody response against human viruses Phase I/II with seasonal quadrivalent launched in Oct healthy adults (1849 years of age) Findings from preclinical studies Crossprotection From preclinical trials (one dose (10 µg), no adjuvant): 100% protection in mice and ferrets against H5N1 Indonesia Independent NIAID heterologous challenge: 100% protection against H5N1 Vietnam 70% protection against H2N2 Japan RecHA failed to protect Challenge against heterologous H5N1 Vietnam Challenge against heterolsubtypic H2N2 Japan Completed Ongoing 7 8 2
3 Efficacy of H7 VLP after 1 st dose in mice 100% protection against lethal challenge with H7N9 H5 VLP clinical results Trial NCT # GMT: 135 (16/16) GMT: 27 (16/16) GMT: 15 (12/16) significantly different from matchedplacebo, p < # significantly different from Alhydrogel, p < 0.05 Note: H7 VLP is not significantly different from adjuvanted groups 100% protection of mice immunized with one dose of 3 µg adj. H7 VLP 62.5% protection of mice immunized with one dose of 3 µg nonadj. H7 VLP 100% protection of mice immunized with 2 nonadj. doses of 3 µg (not shown) Phase I ongoing 9 Seroconversion rate (4fold increase) D42 Target of 40% Seroprotection rate (% 1:32) D42 Target of 70% 20 µg 2.5µg GLAAF (ID) 20 µg 2.5µg GLAAF (IM) H5 VLP (A/Indonesia) Medicago 20 µg (ID) 20 µg 0.5mg Alhydrogel(IM) H5N1 split (A/Vietnam) 90 µg (IM) 65.0% 80.0% 52.6% 83.3% 43.8% 70.0% 85.0% 52.6% 88.9% 50.0% GMI D42/D0 Target of H5 VLP with GLAAF IM or ID or with alum IM meet the 3 CHMP criteria for licensure of pandemic vaccines 10 Phase I/II trial with seasonal quadrivalent VLP vaccine Safety profile Phase I/II with seasonal quadrivalent VLP vaccine (trial NCT ) TEST MATERIAL Seasonal quadrivalent VLP Influenza vaccine Seasonal quadrivalent VLP Influenza vaccine TREATMENT GROUP Treatment Grp 1 (low dose) Treatment Grp 2 (medium dose) NO. OF SUBJECTS DOSE LEVEL 3 µg per strain\ total of 12 µg HA 9 µg per strain\ total of 36 µg HA ADMINISTERED ON DAY % 90% 80% 70% 60% 50% Solicited local reactions, during the first 7 days after immunization Severe Moderate Mild Seasonal quadrivalent VLP Influenza vaccine Treatment Grp 3 (high dose) µg per strain\ total of 60 µg HA 0 40% 30% 20% 100mM phosphate buffer 150 mm NaCl 0.01% Tween 80 Treatment Grp 4 (placebo) 30 None 0 10% 0% 11 PAIN ERYTHEMA SWELLING 3
4 Responsive CD4 to H1 pept. pool per 10 6 CD4 T cells Responsive CD4 to H1 pept. pool per 10 6 CD4 T cells Safety profile Phase I/II with seasonal quadrivalent VLP vaccine (trial NCT ) 50% 45% Solicited systemic reactions, during the first 7 days after immunization Phase I/II with Quadrivalent VLP vaccine HemagglutinationInhibition Antibody Titers 21 days postdose (trial NCT ) Strain Criteria Groups 3 µg/strain 9 µg/strain 15 µg/strain 40% Severe Moderate 4fold (%) % 30% Mild OT over 38C H1N1 1:40 (%) GMI 2.5 (%) % 4fold (%) % 15% H3N2 1:40 (%) GMI 2.5 (%) % 4fold (%) % 0% B/Brisbane 1:40 (%) GMI 2.5 (%) fold (%) B/Wisconsin 1:40 (%) GMI 2.5 (%) FATIGUE HEADACHE MUSCLES ACHES JOINT ACHES CHILLS FEVER GENERAL SWELLING IN SWELLING IN SWELLING IN DISCOMFORT THE AXILLA THE GROIN THE NECK Meets CHMP criteria 14 Phase I/II with Quadrivalent VLP vaccine MicroNeutralisation antibody titers 21 days postdose (trial NCT ) Strain Criterium Groups 3 µg/strain 9 µg/strain 15 µg/strain A single dose of H1 VLP vaccine induced polyfunctional T cell response PBMCS collected 6month postvaccination, trial NCT Peptide pool stimulation H1 H1 VLP stimulation H1N1 H3N2 GMT fold (%) GMT fold (%) GMT B/Brisbane 4fold (%) B/Wisconsin GMT fold (%) B/Mass GMT (Yamagata strain for season) 4fold (%) IFNg IL2 TNFa H1 VLP Fluzone H1 VLP Fluzone H1 VLP Fluzone Pie Arc Chart legend Arc Legend Pie Category H1 VLP Fluzone Test Results IFNg IL2 H1 VLP TNFa Fluzone
5 Responsive CD4 cells to H2 VLP per 10 6 CD4 cells Responsive CD4 cells to H7 VLP per 10 6 CD4 cells Responsive CD4 cells to H5 peptides per 10 6 CD4 cells H1 VLP induces crossreactive T cells to H5N1 PBMCs collected 6 months after vaccination, trial NCT Polyfunctional CD4 T Cell response to H5 Homotypic response after vaccination with H5 VLP (21 days postboost, trial NCT ) 10 µg H5 VLP Alhy 15 µg H5 VLP Alhy 20 µg H5 VLP Alhy Crossreactive responses of CD4 (left panel) and CD8 (right panel) T cell responses from the H1 VLPvaccinated patients ex vivo stimulated with H5 VLP. The symbol indicates statistically significant differences between twogroups analyzed by the MannWhitney test (P 0.05). More CD4 & CD8 T cells crossreactive for H5N1 compared to eggbased and placebo Crossprotective effects similar to those reported for H5N1 vaccines administered with oilinwater adjuvants 17 IL2 IFNg TNFa Cytokines expressing profile in CD4 cells after ex vivo stimulation with H5 peptides pool 18 Statistically significant compared to placebo Crossreactive CD4 T Cell response to HA of H2N2 Heterotypic (group 1) response after vaccination with H5 VLP (trial NCT ) Crossreactive CD4 T Cell response to HA of H7N9 Heterotypic (group 2) response after vaccination with H5 VLP (trial NCT ) 10 µg H5 VLP Alhy 10 µg H5 VLP Alhy 15 µg H5 VLP Alhy 20 µg H5 VLP Alhy 15 µg H5 VLP Alhy 20 µg H5 VLP Alhy Statistically significant compared to placebo Statistically significant compared to placebo IL2 IFNg TNFa One nonadj H5 VLP dose: 70% protection against H2N2 in mice IL2 IFNg TNFa Cytokines expressing profile in CD4 cells after ex vivo stimulation with H2 VLP 19 Cytokines expressing profile in CD4 cells after ex vivo stimulation with H7 VLP 20 5
6 Conclusion Conclusion H5 VLP pandemic vaccine When formulated with alum, induce HI antibody titers that meet surrogate correlates of protection based on HI antibody titers Induce polyfunctional T cell response H7 VLP pandemic vaccine Induced a comparable or superior antibody response to H5 VLP in 2 animal models Currently evaluated in humans formulated with alum Seasonal Quadrivalent vaccine Good safety profile Dosages of 9 and 15 µg per strain meets the CHMP criteria for licensure of seasonal vaccines Induced a good MN antibody response crossreactive towards other strain (B Yamagata) Animal challenge studies and CMI results during clinical trials with plantbased VLP vaccines show potential for crossprotection H5 vs. H1, H2 & H7 demonstrated to date CMI important for seasonal flu vaccine in terms of crossprotection 2009 H1N1 pandemic: elderly protected by memory CD4 response from previous H1N1 infections (Hsu et al Int J Infect Dis) Shown to protect humans in the absence of antibodies (Wilkinson 2012) Characterization ongoing in current Phase I/II with seasonal VLP vaccine Plantbased VLPs Numerous manufacturing advantages Good safety and immunogenicity results in ~1,000 subjects Good antibody response Crossprotective effects possibly related to strong T cell response Good compromise to natural infection Future plans To evaluate the alumadjuvanted pandemic vaccine in a pivotal phase 3 trial To increase the safety database Will include a lottolot consistency trial Merci! Thank you! Arigatō! To continue the clinical evaluation of the seasonal quadrivalent VLP vaccine Larger group size to evaluate CBER criteria for licensure In healthy adults In the elderly population 23 6
Investor Presentation. December 2012 TSX: MDG OTCQX: MDCGF
Investor Presentation December 2012 TSX: MDG OTCQX: MDCGF Forward-Looking Statements and Disclaimers This presentation contains forward-looking information and statements which constitute forwardlooking
More informationCatching the Flu: A Photo Essay
May 2006 Catching the Flu: A Photo Essay As it tests a new way of making vaccines, TechnoVax is targeting the deadly 1918 flu virus. By Stephan Herrera (MIT Technology Review) Jose Galarza is the CEO of
More informationGlaxoSmithKline Pandemic Influenza Portfolio
GlaxoSmithKline Pandemic Influenza Portfolio Schladminger Gesundheitsgespräche 06. June 2009 Responding to the Pandemic Influenza Threat - WHO Recommended Strategic Actions Non-pharmacological measures
More informationFAQs on Influenza A (H1N1-2009) Vaccine
FAQs on Influenza A (H1N1-2009) Vaccine 1) What is Influenza A (H1N1-2009) (swine flu) 1? Influenza A (H1N1-2009), previously known as "swine flu", is a new strain of influenza virus that spreads from
More informationRecombinant protein vaccines produced in insect cells
Recombinant protein vaccines produced in insect cells Manon M.J. Cox Hong Kong 25JAN2013 Flublok BREAKING NEWS 16JAN2013 FDA approves Flublok for the prevention of influenza in adults 18-49 years old The
More informationHSA Consumer Guide. Understanding Vaccines, Vaccine Development and Production. www.hsa.gov.sg November 2009. How a Vaccine Works.
November 2009 Understanding Vaccines, Vaccine Development and Production Vaccines, in general, help protect people from harmful infections before they come in contact with the disease. Vaccines may also
More informationswine flu vaccination:
swine flu vaccination: what you need to know Flu. Protect yourself and others. Contents What is swine flu?............... 3 About the swine flu vaccine....... 4 What else do I need to know?...... 8 What
More informationMontanide TM adjuvants for stimulation of cellular immune response in FMD vaccines
Montanide TM adjuvants for stimulation of cellular immune response in FMD vaccines Sébastien Deville, Juliette Ben Arous, François Bertrand, Laurent Dupuis FAO-ICAR Conference Feb 13-15, New Delhi An affiliate
More informationAdjuvant Development for IPV. Martin Friede Ph.D. Initiative for Vaccine Research
Adjuvant Development for IPV Martin Friede Ph.D. Initiative for Vaccine Research Role of adjuvants in vaccine development Enable subunit antigens to induce protective immune response Achieve protective
More informationBE SURE. BE SAFE. VACCINATE.
DON T GET OR GIVE THE FLU THIS YEAR THANK YOU Vaccination is the only protection. www.immunisation.ie BE SURE. BE SAFE. VACCINATE. FLU VACCINE 2013-2014 Healthcare workers prevent the spread of flu and
More informationMINISTRY OF HEALTH PANDEMIC INFLUENZA A / H1N1 2009 VACCINE FREQUENTLY ASKED QUESTIONS
Government of the Republic of Trinidad and Tobago MINISTRY OF HEALTH PANDEMIC INFLUENZA A / H1N1 2009 VACCINE FREQUENTLY ASKED QUESTIONS Influenza vaccines are one of the most effective ways to protect
More informationFDA Update on the H1N1 Flu Vaccine and Antiviral Medications
FDA Update on the H1N1 Flu Vaccine and Antiviral Medications Beth Fabian Fritsch, R.Ph., M.B.A. Commander, U.S. Public Health Service Health Programs Coordinator Office of Special Health Issues Food and
More informationPandemic Influenza Vaccines: Lessons Learned from the H1N1 Influenza Pandemic
Pandemic Influenza Vaccines: Lessons Learned from the H1N1 Influenza Pandemic Nancy J. Cox, Ph.D. Director, Influenza Division Director WHO Collaborating Center for Influenza NCIRD, Centers for Disease
More informationSee 17 for PATIENT COUNSELING INFORMATION Revised: 05/2016 FULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use QUADRIVALENT safely and effectively. See full prescribing information for QUADRIVALENT. QUADRIVALENT
More informationOverview of Phase 1 Oncology Trials of Biologic Therapeutics
Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of
More informationVaccine Production Strategies: Ensuring Alignment and Sustainability
Vaccine Production Strategies: Ensuring Alignment and Sustainability Second WHO Consultation on Global Action Plan for Influenza Vaccines (GAP-II) Robert W Malone, MD, MS Consulting, Vaccines and Biologicals
More informationMedia Contacts: Annick Robinson Investor Contacts: Justin Holko (438) 837-2550 (908) 740-1879 annick.robinson@merck.com
News Release FOR IMMEDIATE RELEASE Media Contacts: Annick Robinson Investor Contacts: Justin Holko (438) 837-2550 (908) 740-1879 annick.robinson@merck.com Merck's HPV Vaccine, GARDASIL 9, now available
More informationFOR INFORMATION CONTACT:
NEWS RELEASE FOR INFORMATION CONTACT: Caroline Calderone Baisley Deborah C. Travers Director of Health Director of Family Health Tel [203] 622-7836 Tel [203] 622-7854 September 10, 2014 For Immediate Release
More informationRegulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective
Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective Office of Vaccines Research and Review Center for Biologics Evaluation and Research U.S. Food
More informationACCESS TO THE SEASONAL FLU VACCINE IN CANADA. How the flu shot makes its way from the laboratory to the doctor s office.
ACCESS TO THE SEASONAL FLU VACCINE IN CANADA How the flu shot makes its way from the laboratory to the doctor s office. Health Canada is the federal department responsible for helping Canadians maintain
More informationProduction of antigens and antibodies in plants: alternative technology?
Production of antigens and antibodies in plants: alternative technology? George Lomonossoff John Innes Centre Norwich, UK ECOPA, Alicante 29 th Sept. 2006 Why use Plants as Biofactories? Produce large
More informationKvartalets)informationsbrev)till)aktieägarna)från)Protein)Sciences)
! M Mertiva!! Pressmeddelande!den!24!september!2015! Kvartalets)informationsbrev)till)aktieägarna)från)Protein)Sciences) Protein(Sciences(Corporation((Protein(Sciences)(har(distribuerat(ett(informationsbrev(till(sina(
More informationSUMMARY AND CONCLUSIONS
SUMMARY AND CONCLUSIONS Summary and Conclusions This study has attempted to document the following effects of targeting protein antigens to the macrophage scavenger receptors by maleylation. 1. Modification
More informationSanofi Pasteur 26 Feb 2015 v0.1 372 Fluzone High-Dose LE6750
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Fluzone High-Dose safely and effectively. See full prescribing information for Fluzone High-Dose.
More informationH1N1 Flu Vaccine Available to All Virginia Beach City Public Schools Students
V i r g i n i a B e a c h C i t y P u b l i c S c h o o l s apple-a-day F o r O u r F a m i l y o f I n t e r e s t e d C i t i z e n s Special Edition H1N1 Flu Vaccine Available to All Virginia Beach
More informationIMPORTANT: PLEASE READ
PART III: CONSUMER INFORMATION combined hepatitis A (inactivated) and hepatitis B (recombinant) vaccine This leaflet is part III of a three-part "Product Monograph" published when was approved for sale
More informationOriginal article: Sumito Inoue*, Yoko Shibata, Noriaki Takabatake, Akira Igarashi, Shuichi Abe, Isao Kubota
Original article: INFLUENCE OF CORTICOSTEROID THERAPY ON THE SERUM ANTIBODY RESPONSE TO INFLUENZA VACCINE IN ELDERLY PATIENTS WITH CHRONIC PULMONARY DISEASES Sumito Inoue*, Yoko Shibata, Noriaki Takabatake,
More informationMAB Solut. MABSolys Génopole Campus 1 5 rue Henri Desbruères 91030 Evry Cedex. www.mabsolut.com. is involved at each stage of your project
Mabsolus-2015-UK:Mise en page 1 03/07/15 14:13 Page1 Services provider Department of MABSolys from conception to validation MAB Solut is involved at each stage of your project Creation of antibodies Production
More informationExperiences with Live Attenuated Influenza Vaccine Trials in Thailand and Future Plan
Experiences with Live Attenuated Influenza Vaccine Trials in Thailand and Future Plan Punnee Pitisuttithum, MBBS,DTM&H,FRCPT Vaccine Trial Center,Faculty of Tropical Medicine, Mahidol University For MOPH,CDC,MU,Geneva
More informationTOWARDS AN HIV VACCINE
why is it so hard to make an HIV vaccine and where are we now? Neal Nathanson, MD Emeritus Professor Department of Microbiology University of Pennsylvania School of Medicine 1 Estimated number of persons
More informationTBE vaccines: immunogenicity, effectiveness and safety
TBE vaccines: immunogenicity, effectiveness and safety Prof. H.Kollaritsch, MD., DTM., Associate professor for Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology,
More informationThe public health risk of influenza in pigs recent insights, key knowledge gaps
The public health risk of influenza in pigs recent insights, key knowledge gaps Prof. Kristien Van Reeth Laboratory of Virology, Faculty of Veterinary Medicine, Ghent University, Belgium H1N1, H3N2 and
More informationSome Intellectual Property Issues Related to H5N1 Influenza Viruses, Research and Vaccines
PREPUBLICATION COPY Some Intellectual Property Issues Related to H5N1 Influenza Viruses, Research and Vaccines Prepared by: Edward Hammond For: Third World Network Updated September 2008 CONTENTS 1. Trends
More informationKey Facts about Influenza (Flu) & Flu Vaccine
Key Facts about Influenza (Flu) & Flu Vaccine mouths or noses of people who are nearby. Less often, a person might also get flu by touching a surface or object that has flu virus on it and then touching
More informationEnter this essay in the English Language Learner (for 5 years or less of English) category: _X_ Yes
Date: 2/24/2015 Student Name: Nikita Skiba Title of Essay: HIV/AIDS treatments Teacher s Name: Cheryl McClure School Name: International School School Address: 445 128th Ave SE Bellevue WA 98005 Enter
More informationPRODUCT MONOGRAPH FLUVIRAL (2015-2016)
PRODUCT MONOGRAPH FLUVIRAL 2015-2016 Trivalent Influenza Vaccine (Split Virion, Inactivated) Suspension for Injection ATC Code J07BB02 Manufactured by: ID Biomedical Corporation of Quebec Quebec, Quebec
More informationH1N1 SWINE FLU PANDEMIC
H1N1 SWINE FLU PANDEMIC 2 PANDEMIC H1N1 SWINE FLU Pandemic H1N1 Swine flu A novel influenza A H1N1 virus emerged from Mexico in April 2009 and spread so rapidly that the World Health Organisation declared
More informationThe immunogenic vaccine against HCV and HBV
National Centre for Research and Development, The immunogenic vaccine against HCV and HBV Katarzyna Grzyb Laboratory of Virus Molecular Biology Intercollegate Faculty of Biotechnology UG-MUG 1 Hepatitis
More informationInformationsbrev.till.aktieägarna.från.Protein.Sciences,.december.2015.
! M Mertiva!! Pressmeddelande!den!28!december!2015! Informationsbrev.till.aktieägarna.från.Protein.Sciences,.december.2015. Protein(Sciences(Corporation((Protein(Sciences)(har(distribuerat(ett(nytt(informationsbrev(till(sina(
More informationNEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds
NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.
More informationSee 17 for PATIENT COUNSELING INFORMATION. Revised: November 2009
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Influenza A (H1N1) 2009 Monovalent Vaccine safely and effectively. See full prescribing information
More informationTechnological platforms
Advitech Advitech is a life sciences & technology company Its mission is to discover and commercialize proprietary and evidence-based natural health products Focus on milk, whey and bovine colostrum R&D,
More informationZika Virus. Fred A. Lopez, MD, MACP Richard Vial Professor Department of Medicine Section of Infectious Diseases
Zika Virus Fred A. Lopez, MD, MACP Richard Vial Professor Department of Medicine Section of Infectious Diseases What is the incubation period for Zika virus infection? Unknown but likely to be several
More informationInfluenza Education Presentation Prepared by Peel Public Health 2014
Influenza Education Presentation Prepared by Peel Public Health 2014 Disclaimer We are pleased to be able to offer you the use of our Influenza PowerPoint presentation for your use. Peel Public Health
More informationFLU VACCINATION - FREQUENTLY ASKED QUESTIONS
FLU VACCINATION - FREQUENTLY ASKED QUESTIONS SEASONAL FLU VACCINATION 2015 2016 As a health care worker, am I required to be vaccinated against influenza (the flu)? It is not mandatory to be vaccinated
More informationCANADA S VACCINE INDUSTRY COMMITTEE
WWW.BIOTECH.CA CANADA S VACCINE INDUSTRY COMMITTEE LEADERSHIP IN GLOBAL HEALTH The Vaccine Industry Committee (VIC), Canada s Voice for Vaccines The VIC is comprised of Canada s major vaccine developers
More informationInfluenza Vaccine Frequently Asked Questions. Influenza Control Program
Influenza Vaccine Frequently Asked Questions Influenza Control Program Influenza or the flu can be a serious contagious disease, which is spread by droplet transmission through close contact with an infected
More informationNOVAVAX INC FORM 424B5. (Prospectus filed pursuant to Rule 424(b)(5)) Filed 03/26/15
NOVAVAX INC FORM 424B5 (Prospectus filed pursuant to Rule 424(b)(5)) Filed 03/26/15 Address 20 FIRSTFIELD ROAD GAITHERSBURG, MD 20878 Telephone 240-268-2000 CIK 0001000694 Symbol NVAX SIC Code 2836 - Biological
More informationExcess mortality in Europe in the winter season 2014/15, in particular amongst the elderly.
Excess mortality in Europe in the winter season 2014/15, in particular amongst the elderly. An analysis of all-cause mortality from 15 European countries participating in the EuroMOMO network (www.euromomo.eu)
More informationHapten - a small molecule that is antigenic but not (by itself) immunogenic.
Chapter 3. Antigens Terminology: Antigen: Substances that can be recognized by the surface antibody (B cells) or by the TCR (T cells) when associated with MHC molecules Immunogenicity VS Antigenicity:
More informationFREQUENTLY ASKED QUESTIONS SWINE FLU
FREQUENTLY ASKED QUESTIONS SWINE FLU Updated 5/6/09 ER FAQ What is swine flu? Swine flu is common disease of pigs and is caused by the same category of influenza virus (influenza A) that causes flu in
More informationNon-clinical development of biologics
Aurigon Life Science GmbH Non-clinical development of biologics Requirements, challenges and case studies Committed to Life. Sigrid Messemer vet. med. M4 Seminar March 10 th 2014 Aurigon - your full service
More informationThe format of this leaflet was determined by the Ministry of Health and its content was checked and approved in May 2013.
The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in May 2013 Havrix 720 Junior 1 NAME OF THE MEDICINAL PRODUCT Havrix 720 Junior 2 QUALITATIVE
More information10. T and B cells are types of a. endocrine cells. c. lymphocytes. b. platelets. d. complement cells.
Virus and Immune System Review Directions: Write your answers on a separate piece of paper. 1. Why does a cut in the skin threaten the body s nonspecific defenses against disease? a. If a cut bleeds, disease-fighting
More informationAV1300 STAFF INFLUENZA IMMUNIZATION AND EXCLUSION POLICY
AV1300 STAFF INFLUENZA IMMUNIZATION AND EXCLUSION POLICY 1.0 PURPOSE To help ensure that those at greatest risk of complications and death from influenza are optimally protected through the appropriate
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion for the approval of TWINRIX Adult. This scientific discussion has been updated until 01 February 2004. For information on changes
More informationRABIES PROPHYLAXIS OF PEOPLE
RABIES PROPHYLAXIS OF PEOPLE Persons can be protected against rabies through a vaccine -- the vaccine which is currently being used is Rabies Human Diploid Cell Vaccine (HDCV). The preexposure series can
More informationDuring the course of this presentation, data from certain clinical studies may be shown. These studies were sponsored independently by Generex.
GENEREX BIOTECHNOLOGY 2009 Annual General Meeting July 30, 2009 Forward Looking Statements During the course of this presentation, it is possible that statements that could be construed as forward-looking
More informationInfluence of Statins on Influenza Vaccine Response in Elderly Individuals
Embargoed until 12:01 A.M. EDT on Thursday, Oct. 29 MAJOR ARTICLE Influence of Statins on Influenza Vaccine Response in Elderly Individuals Steven Black, 1 Uwe Nicolay, 2 Giuseppe Del Giudice, 3 and Rino
More informationWobenzym. Wobenzym Keeps you moving.
Wobenzym PS Helps to maintain healthy joints, mobility and flexibility Relief from everyday aches, pains and muscle soreness Speeds recovery following exertion Supported by over 200 clinical trials Wobenzym
More informationProduction of proteins for medical use in TG silkworms
Production of proteins for medical use in TG silkworms Development of animal therapeutic drugs Collaborative development of influenza vaccines with Institute of Biological Resource Collaborative development
More informationInfluenza virus Vaccine, Split Virus, When administered to individuals 3 years or older, for intramuscular use (Agriflu)
Adult Immunization Codes State and School Employees Life and Health Insurance Plan Not Subject to Calendar Year Deductible 100% of allowable for covered procedures Payable only for Network Providers (In-State
More informationWHO Technology Transfer Initiative: supporting grantees through the next phase
7th Meeting with International Partners on Prospects for Influenza Vaccine Technology Transfer to Developing Country Vaccine Manufacturers WHO Technology Transfer Initiative: supporting grantees through
More informationI thank them for their openness, transparency, and willingness to work with WHO to address this newly emerging infection.
I N F L U E N Z A - L I K E I L L N E S S O U T B R E A K I N T H E U S A N D M E X I C O T r a n s c r i p t o f G L O B AL T E L E P H O N E N E W S C O N F E R E N C E w i t h D r M a r g a r e t C
More informationRoche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA
Media Release Basel, 28 June 2016 Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA OCREVUS is the first investigational medicine
More informationInfluenza Surveillance in Thailand 2012
Influenza Surveillance in Thailand 2012 Thitipong Yingyong Bureau of Epidemiology, Thai-DDC 6 th NIC&Flu Surveillance Meeting, Vietnam May 29 th,2012 Influenza surveillance system R506 > Influenza, Pneumonia
More informationBreakthroughs and Big Questions: AIDS vaccine research in 2014
Breakthroughs and Big Questions: AIDS vaccine research in 2014 Mary A. Marovich Director, Vaccine Research Program Division of AIDS NIAID/NIH May 19, 2014 1 Future of HIV-1 vaccines is bright Major breakthroughs
More informationHow To Use An Antibody
GUIDELINES FOR THE PRODUCTION OF ANTIBODIES IN LABORATORY ANIMALS Table of Contents 1. Purpose 2. Choice of Species and Strain 3. Immunizing Antigen 4. Procedures for Polyclonal Antibody Production 5.
More informationAnti-CD38 anti-cd3 bispecific antibody in multiple myeloma
Anti-CD38 anti-cd3 bispecific antibody in multiple myeloma David E. Szymkowski Senior Director, Biotherapeutics Proteins by Design 1960s...1980s...2000s... Where are the bispecific antibody drugs? J Exp.
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 10 October 2007 Doc. Ref. COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON POTENCY TESTING OF CELL BASED IMMUNOTHERAPY
More informationChapter 3. Immunity and how vaccines work
Chapter 3 Immunity and how vaccines work 3.1 Objectives: To understand and describe the immune system and how vaccines produce immunity To understand the differences between Passive and Active immunity
More informationTrial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine
The new england journal of medicine original article Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine Tristan W. Clark, M.R.C.P., Manish Pareek, M.R.C.P., Katja Hoschler, Ph.D., Helen
More informationCMP Antibody Production Service
CMP Antibody Production Service Polyclonal antibody production has become an essential part of many research projects at Texas A&M. Standardization of production procedures and the performance of the procedures
More informationViruses. Viral components: Capsid. Chapter 10: Viruses. Viral components: Nucleic Acid. Viral components: Envelope
Viruses Chapter 10: Viruses Lecture Exam #3 Wednesday, November 22 nd (This lecture WILL be on Exam #3) Dr. Amy Rogers Office Hours: MW 9-10 AM Too small to see with a light microscope Visible with electron
More informationOREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS Human Papilloma Virus Vaccines (HPV)
OREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS Human Papilloma Virus Vaccines (HPV) Revisions as of 01-01-2016 Vaccination age changed to clients 7 years of age Removal of adolescent well
More informationGuidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines
FINAL ENGLISH ONLY Guidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines World Health Organization 2013 All rights reserved. Publications of the World Health Organization
More informationVaccination policy, vaccine development and manufacturing in Japan. Yoichiro Kino, Ph.D Executive Managing Director Kaketsuken
Vaccination policy, vaccine development and manufacturing in Japan Yoichiro Kino, Ph.D Executive Managing Director Kaketsuken Background of KAKETSUKEN Organization Name The ChemoSeroTherapeutic Research
More informationTG1050, A NOVEL IMMUNOTHERAPEUTIC TO TREAT CHRONIC HEPATITIS B, CAN CONTROL HBsAg AND PROVOKE HBsAg SEROCONVERSION IN HBV-PERSISTENT MOUSE MODELS
TG1050, A NOVEL IMMUNOTHERAPEUTIC TO TREAT CHRONIC HEPATITIS B, CAN CONTROL HBsAg AND PROVOKE HBsAg SEROCONVERSION IN HBV-PERSISTENT MOUSE MODELS Karine Lélu 1, Alexei Evlachev 1, Roland Kratzer 1, Sarah
More informationThe Immune System. 2 Types of Defense Mechanisms. Lines of Defense. Line of Defense. Lines of Defense
The Immune System 2 Types of Defense Mechanisms Immune System the system that fights infection by producing cells to inactivate foreign substances to avoid infection and disease. Immunity the body s ability
More informationInfluenza and Pandemic Flu Guidelines
Influenza and Pandemic Flu Guidelines Introduction Pandemic flu is a form of influenza that spreads rapidly to affect most countries and regions around the world. Unlike the 'ordinary' flu that occurs
More informationInfluenza antibody profiling by protein microarray. Marion Koopmans, Professor of public health virology Head Viroscience department
Influenza antibody profiling by protein microarray Marion Koopmans, Professor of public health virology Head Viroscience department Influenza serology applications 1. Evaluation of vaccine response (functional
More informationPREVNAR 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM 197 Protein]) Suspension for intramuscular injection Initial US Approval: 2010
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PREVNAR 13 safely and effectively. See full prescribing information for PREVNAR 13. PREVNAR 13 (Pneumococcal
More informationCanine Distemper Virus
Canine Distemper Virus Canine Distemper (CD) is a highly contagious infectious disease of dogs worldwide caused by the canine distemper virus (CDV). It is often fatal. CD is a multisystemic disease that
More informationOverview of Drug Development: the Regulatory Process
Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Adapted from course taught by Cato Research Background: Roger
More informationFrom Research Services and Process Development to GMP Manufacturing
From Research Services and Process Development to GMP Manufacturing P a r ag o n B i o s e r v i c e s, I n c. A contract research and GMP manufacturing organization (CMO) with a focus on the development
More informationCellular Implants as mini-factories for the production of therapeutic antibodies against Altzheimer s disease. rapport research week Jonas Schiffmann
Cellular Implants as mini-factories for the production of therapeutic antibodies against Altzheimer s disease rapport research week Jonas Schiffmann Supported by Aurélien Lathuilière, Bernard Schneider
More informationChapter 18: Applications of Immunology
Chapter 18: Applications of Immunology 1. Vaccinations 2. Monoclonal vs Polyclonal Ab 3. Diagnostic Immunology 1. Vaccinations What is Vaccination? A method of inducing artificial immunity by exposing
More informationNorthern Ireland swine flu helpline: 0800 0514 142
15/09/2009 Page 1 Information for special school principals on swine influenza A (H1N1) This information sheet gives general information about swine infl uenza A (H1N1) (swine fl u) as well as addressing
More informationSwine Flu and Common Infections to Prepare For. Rochester Recreation Club for the Deaf October 15, 2009
Swine Flu and Common Infections to Prepare For Rochester Recreation Club for the Deaf October 15, 2009 Supporters Deaf Health Community Committee Members Julia Aggas Cathie Armstrong Michael McKee Mistie
More informationLOEWENBERG SCHOOL OF NURSING LOEWENBERG SCHOOL OF NURSING HEALTH EXAMINATION FORM (FORM 003)
SECTION I: To be completed by STUDENT: Name: DOB: Address: Phone (H): Phone (C): Health History: Please complete the following information: Recent weight loss or gain Fatigue, fever, sweats Difficulty
More informationFocus on Preventing Disease. keeping an eye on a healthy bottom line. Cattle Industry
Focus on Preventing Disease keeping an eye on a healthy bottom line Cattle Industry Multimin + VACCINES : University OF FLORIDA study data Study 1 Effect of injectable trace minerals on the humoral immune
More informationWhy use passive immunity?
Vaccines Active vs Passive Immunization Active is longer acting and makes memory and effector cells Passive is shorter acting, no memory and no effector cells Both can be obtained through natural processes:
More informationBactériophages et Mucoviscidose
Bactériophages et Mucoviscidose Laurent DEBARBIEUX Département de Microbiologie Interactions Bactériophages-Bactéries chez l'animal Bacteriophages belong to viruses infecting microbes DNA capside tail
More informationValneva Reports Preliminary FY 2013 Revenues of EUR 36.0m and Cash Position of EUR 40.2m at End of 2013
Valneva Reports Preliminary FY 2013 Revenues of EUR 36.0m and Cash Position of EUR 40.2m at End of 2013 Revenue Ahead of Guidance and Cash Target Met in First year Following Merger Total revenues and grants
More informationDevelopment of an Influenza Risk Assessment Tool
Development of an Influenza Risk Assessment Tool Susan C. Trock 1, Stephen A. Burke 2 & Nancy J. Cox 1 1 Influenza Division, NCIRD, CDC 2 Battelle Atlanta Analytical Services, Atlanta, GA Foreign & Emerging
More informationThe clinical studies have been performed in children, adolescents and adults, from 4 years up to 55 years of age.
NAME OF THE MEDICINE TdaP-Booster. Diphtheria, tetanus and pertussis (acellular mono-component) vaccine (adsorbed, reduced antigen content). DESCRIPTION TdaP-Booster is a suspension for injection in pre-filled
More informationDon t gamble on your HERD S health.
Don t gamble on your HERD S health. Boehringer Ingelheim Vetmedica, Inc. is a familyowned company that strives to deliver high-quality, innovative vaccines to the cattle industry. The Pyramid vaccine line
More informationCONTENT. Chapter 1 Review of Literature. List of figures. List of tables
Abstract Abbreviations List of figures CONTENT I-VI VII-VIII IX-XII List of tables XIII Chapter 1 Review of Literature 1. Vaccination against intracellular pathogens 1-34 1.1 Role of different immune responses
More informationNurse Aide Training Program Application Checklist
Nurse Aide Training Program Application Checklist The following checklist must be completed before enrolling in the Nurse Aide Training course: Complete, sign, and date the Application Form Have the physical
More informationUseful contacts. Call 0800 1 513 513 to hear the latest information on swine flu. England: www.nhs.uk www.direct.gov.uk/swineflu
Useful contacts Call 0800 1 513 513 to hear the latest information on swine flu. England: www.nhs.uk www.direct.gov.uk/swineflu Scotland: www.nhs24.com Wales: www.nhsdirect.wales.nhs.uk www.wales.gov.uk/health
More information